El Fakih Riad, Rasheed Walid, Hawsawi Yousef, Alsermani Maamoun, Hassanein Mona
King Faisal Specialist Hospital and Research Center Riyadh, Riyadh 11211, Saudi Arabia.
Cells. 2018 Jan 8;7(1):4. doi: 10.3390/cells7010004.
The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML.
FMS样酪氨酸激酶3（FLT3）通路在细胞增殖、存活和分化中起重要作用。FLT3突变的急性髓系白血病（AML）患者在初诊时疾病负担重，预后差。多年来已研发出多种FLT3抑制剂。第一代抑制剂大多是非特异性的，而第二代抑制剂更具特异性且效力更强。这些抑制剂几乎用于治疗FLT3突变AML患者的所有疾病阶段，包括诱导缓解、巩固治疗、维持治疗、复发以及造血细胞移植（HCT）后。在本文中，我们将综述FLT3抑制剂在AML中的应用。
